© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 19, 1556-1558,
October 4, 2000
© 2000 Oxford University Press
NEWS |
Surveys Identify Barriers to Participation in Clinical Trials
First in a two-part series.
According to estimates, fewer than 3% of adults with cancer participate in clinical trials, a rate that has long been the subject of intense hand wringing in the clinical research community. Recent surveys of oncologists, people with cancer, and the general public are beginning to replace speculation about barriers to participation with hard data, and these data are suggesting concrete strategies for increasing enrollment.
The most recent of these surveys was conducted by Harris Interactive Inc. and co-sponsored by several groups, including the Coalition of National Cancer Cooperative Groups, the Cancer Research Foundation of America, the Cancer Leadership Council, and the Oncology Nursing Society. The survey included telephone interviews with a random sample of 1,000 adults, including oversamples of 200 African Americans and 200 Hispanics;
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Enhancing Oncologist Participation in Research J. Oncol. Pract, November 1, 2009; 5(6): 309 - 311. [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Williams, P. B. Mullan, and D. Todem Moving from theory to practice: implementing the Kin KeeperSM Cancer Prevention Model Health Educ. Res., April 1, 2009; 24(2): 343 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. T. Nguyen, C. P. Somkin, Y. Ma, L.-C. Fung, and T. Nguyen Participation of Asian-American Women in Cancer Treatment Research: A Pilot Study J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 102 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Avenell, A. M Grant, M. McGee, G. McPherson, M. K Campbell, M. A McGee, and RECORD Trial Management Group The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design Clinical Trials, December 1, 2004; 1(6): 490 - 498. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Varterasian, H. Fingert, M. Agin, M. Meyer, M. Cooney, T. Radivoyevitch, A. Dowlati, B. Overmoyer, N. Levitan, K. Robertson, et al. Consideration of QT/QTc Interval Data in a Phase I Study in Patients with Advanced Cancer Clin. Cancer Res., September 1, 2004; 10(17): 5967 - 5969. [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Wright and M. N. Levine Researching the Cost of Research J. Clin. Oncol., November 15, 2003; 21(22): 4081 - 4082. [Full Text] [PDF]
|
|
|
|
|
|
K. W.L. Yee, J. L. Pater, L. Pho, B. Zee, and L. L. Siu Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier? J. Clin. Oncol., April 15, 2003; 21(8): 1618 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Wagle, D. P. Goldman, and M. Kilgore Re: Surveys Identify Barriers to Participation in Clinical Trials J Natl Cancer Inst, February 7, 2001; 93(3): 238a - 239a. [Full Text]
|
|